1 |
Lee J, Liu S, Wang Y, Liang Y, Jablons DM. MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway. Oncotarget 2022;13:1217-1236. [DOI: 10.18632/oncotarget.28305] [Reference Citation Analysis]
|
2 |
Zhong X, Ma H. Targeting CD38 for acute leukemia. Front Oncol 2022;12:1007783. [DOI: 10.3389/fonc.2022.1007783] [Reference Citation Analysis]
|
3 |
Mustafa N, Azaman MI, Ng GGK, Chng WJ. Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies. Biomolecules 2022;12:1261. [DOI: 10.3390/biom12091261] [Reference Citation Analysis]
|
4 |
Szlasa W, Czarny J, Sauer N, Rakoczy K, Szymańska N, Stecko J, Kołodziej M, Kaźmierczak M, Barg E. Targeting CD38 in Neoplasms and Non-Cancer Diseases. Cancers 2022;14:4169. [DOI: 10.3390/cancers14174169] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
5 |
Maynard RS, Hellmich C, Bowles KM, Rushworth SA. Acute Myeloid Leukaemia Drives Metabolic Changes in the Bone Marrow Niche. Front Oncol 2022;12:924567. [DOI: 10.3389/fonc.2022.924567] [Reference Citation Analysis]
|